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Background: Compared with FISH and qRT-PCR analyses, immunohistochemistry (IHC) is the preferred screening
test in most pathology practices for ALK-rearrangement detection. With 100% sensitivity and 98% specificity, the
VENTANA ALK (D5F3) IHC assay has been approved in the EU and some Asian countries for ALK-rearrangement
detection. However, an automated Ventana IHC platform is not available in most pathology labs. In this study, we
evaluated the applicability of conventional IHC with D5F3 antibody in routine pathological practice and proposed
detection methods and procedures that ensure that patients with ALK+ are not missed.
Methods: FISH and IHC analyses were performed on 297 lung adenocarcinoma cases. VENTANA IHC and qRT-PCR
assay were applied to evaluate ALK-fusion status in the discordant cases of FISH and IHC. The association of ALK+
with clinicopathological characteristics was statistically analyzed.
Results: IHC had 100% sensitivity and 81.8% specificity for detecting ALK+. Eight ALK-expressed cases were ALK-,
five of which had ALK fusion detected by qRT-PCR analysis. Three of these five cases showed ALK expression using
VENTANA IHC assay. ALK+ was associated with younger age and lymph node metastasis in this Chinese lung
adenocarcinoma patient cohort.
Conclusions: The advantages of low cost and 100% sensitivity allow conventional IHC to serve as a robust
diagnostic tool for screening patients with ALK+, especially in pathology labs without a VENTANA IHC platform. For
cases in which ALK is weakly expressed, qRT-PCR is necessary as a diagnostic test for ALK-fusion detection.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2269448351088278.
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Lung adenocarcinomaIntroduction
Lung cancer is the most common cause of cancer death
worldwide, estimated to be responsible for nearly 1.38
million cancer deaths per year [1]. Despite improve-
ments in the prevention and treatment of lung cancer,
the overall 5-year survival rate remains at 15% [2]. Ef-
forts have been made to develop new treatment strat-
egies. In recent years, rearrangements of the anaplastic
large cell kinase (ALK) gene have been discovered in* Correspondence: lindm3@163.com
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stated.approximately 5% of lung adenocarcinomas, resulting in
the constitutive expression of a fusion protein - most
commonly EML4-ALK - with oncogenic activity [3-7].
Crizotinib, a potent and specific small molecule inhibitor
of both ALK and c-MET tyrosine kinases [8-10], was ap-
proved by the Food and Drug Administration (FDA) for
the treatment of non-small-cell lung cancer (NSCLC)
patients with ALK gene rearrangement (ALK+).
The FDA-approved Vysis ALK Break Apart FISH
Probe Kit (Abbott Molecular) was mandated for ALK+
testing in crizotinib trials, which in a sense indicates that
FISH analysis has been clinically validated. However, the
FISH detection of ALK gene rearrangement in routined. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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financial and technical problems. Theoretically, reverse
transcriptase-polymerase chain reaction (RT-PCR) is a
standard method for determining the fusion genes, but
the requirement of fresh frozen tissue samples for
extracting RNA has limited its application in clinical
practice.
IHC is relatively inexpensive and faster and is per-
formed routinely in most surgical pathology practices.
Mutation-specific IHC has been demonstrated as a reli-
able prescreening test for detecting EGFR mutations in
lung adenocarcinoma [11]. Recently, a fully automated
VENTANA ALK (D5F3) assay was developed using
D5F3 primary antibody (commercialized by Cell Signal-
ing Technology or CST) and VENTANA OptiView DAB
detection for use with VENTANA automated platforms.
Our group demonstrated that the sensitivity and specifi-
city of the VENTANA ALK assay were 100% and 98%,
respectively [12]. The VENTANA ALK (D5F3) IHC
assay was approved to detect ALK rearrangement in
pathology practice in the EU and some Asian countries,
including China and Japan. However, the application of
the VENTAMA ALK IHC assay requires a VENTANA
automated platform, which is not available in most path-
ology labs. In this study, we applied IHC analysis using
CST’s D5F3 antibody to detect ALK rearrangement in a
Chinese lung adenocarcinoma patient cohort to assess
the sensitivity and specificity of IHC analysis. In the
third detection method, a qRT-PCR assay (Amoy Diag-
nostics, Xiamen, China) approved by European Con-
formity (CE marking) and the China Food and Drug
Administration (CFDA), was applied on formalin-fixed
paraffin embedded (FFPE) samples to analyze the dis-
cordant cases of IHC and FISH.Materials and method
Clinical materials and tissue microarray (TMA)
construction
This study included 297 FFPE samples with lung adeno-
carcinoma diagnosed at the Cancer Institute and Hospital,
Chinese Academy of Medical Sciences (CICAMS) in
Beijing, between January 2009 and March 2012. Among
the 297 cases, 218 were unselected and 79 cases were not
effectively treated using conventional treatment.
Among the 218 unselected cases, 178 (with enough
tissue) were constructed onto seven TMAs to represent
biopsies. A 1.5 mm diameter core was taken from the
cancer area based on hematoxylin and eosin (H&E)-
stained sections of each sample. The remaining 39 unse-
lected cases (without enough tissue) and 79 selected
cases were cut into tissue sections. In the cases where
tissue sections/cores fell off the slides during FISH or
IHC analysis, tissue sections were re-cut. The collectionof these specimens was approved by the National Cancer
Center Ethics Committee.
The patients’ medical records were reviewed to obtain
their clinicopathological parameters including age at
diagnosis, sex, smoking history, tumor size, histological
classification and pathological TNM stage.
IHC
Immunohistochemical staining was performed on 4 μm-
thick FFPE tissue sections or TMAs. Briefly, the slides
were deparaffinized and antigen retrieval was then per-
formed in a steam cooker for 1.5 minutes in 1 mM
EDTA, pH 9.0 (Maixin Biological Techology Co. Ltd.,
Fuzhou, China). ALK (D5F3) rabbit monoclonal (Cell
Signaling Technology, Danvers, MA, USA) was applied
at 1:150 in SigalStain antibody diluent (Cell Signaling
Technology, Danvers, MA, USA) for 1 h. Universal sec-
ondary antibody (DAKO) was applied for 15 min. Diami-
nobenzidine or 3-amino-9-ethylcarbazole was used as
chromogens and slides were counterstained with haema-
toxylin before mounting.
The criteria for scoring ALK were as follows. First,
the intensity was graded as 0, negative; 1, weak (light
brown); 2, moderate (brown); and 3, strong (dark
brown). Second, the proportion of positive tumor cells
was graded: 0, no positive cells; 1, <10%; 2, 11%-30%; 3,
31%-50%; 4, 51-70%; and 5, >70%. A final score was de-
rived by adding the two primary scores. Final scores of 0
were defined as “negative expression” (−); scores of 2–5
as “weakly positive expression” (+); and scores of 6–8 as
“strongly positive expression” (++).
Fully automated VENTANA ALK (D5F3) IHC analysis
was performed as previously described [12]. According
to the manufacture’s scoring algorithm, a binary scoring
system (positive or negative for ALK status) was adopted
to evaluate the staining results. The presence of strong
granular cytoplasmic staining in tumor cells (any per-
centage of positive tumor cells) was considered to be
ALK positive while the absence of strong granular cyto-
plasmic staining in tumor cells was deemed to be ALK
negative.
FISH
FISH was performed on 3 μm-thick FFPE tumor tissues
using a break-apart probe specific to the ALK locus
(Vysis LSI ALK Dual Color, Break Apart Rearrangement
Probe; Abbott Molecular, Abbott Park, Illinois, USA) ac-
cording to the manufacturer’s instructions. Tumor cells,
the nuclei of which had one or more FISH signals of
each color, were enumerated. A positive cell was defined
as one in which the nucleus had split signals (two or
more signal diameters apart) or a single orange signal
(deleted green signal) in addition to fused and/or split
signals. A sample was considered positive if >25 cells out
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(10 to 50%), another 50 tumor cells were counted. If the
average percentage of positive cells in 100 tumor cells
was <15% (<15/100), the sample was considered nega-
tive. If the average percentage of positive cells was ≥15%
(≥15/100), the sample was considered positive. TMA
cores with high backgrounds or very weak signals that
affected the signal assessment were excluded from the
analysis.
Real-time quantitative reverse transcription PCR
(qRT-PCR)
The EML4-ALK fusion mRNA was detected by qRT-
PCR using an AmoyDx EML4-ALK Fusion Gene Detec-
tion Kit (Amoy Diagnostics, Xiamen, China). Briefly,
total RNA was extracted with an AmoyDx FFPE RNA
Kit (Spin Column) from 5–10 μm-thick FFPE sections
with over 70% tumor cells. For each sample, 100–500 ng
of extracted RNA was used for reverse transcription into
cDNA at 42°C for 1 h. Real-time PCR was then carried
out in each of the four reactions of the EML4-ALK
Fusion Gene Detection Kit according to the manufac-
turer’s protocol. Reaction 1 amplifies EML4-ALK vari-
ants 1, 2, 3a and 3b (variants 1/2/3a/3b); reaction 2
amplifies EML4-ALK variants 4 and 4′; reaction 3 ampli-
fies EML4-ALK variants 5a, 5b, 5′ and 8 (variants 5a/5b/
5′/8); and reaction 4 amplifies the reference gene
beta-actin. All of the assays were performed on an Agi-
lent Mx3000P QPCR instrument (Agilent Technologies,
Santa Clara, CA). The following PCR procedure was
used: an initial denaturation at 95°C for 5 min followed
by 95°C for 25 s, 64°C for 20 s and 72°C for 20 s to en-
sure the specificity and 31 cycles of 93°C for 25 s, 60°C
for 35 s and 72°C for 20 s to perform the data collection.
The quantitative judgment was according to the fusion
fluorescence signal. Assay reactions achieving Ct values
of ≤30 cycles were considered positive for one of the
variants detected by that reaction mixture. A housekeep-
ing gene (beta-actin) was used to control the integrity of
the RNA.
Statistical analysis
The statistical analysis of the tumors’ size and age was
carried out using Student’s t tests. The values are shown
as mean ± SD. The relationship between ALK+ and
clinicopathological variables was analyzed with the
chi-square test. Statistical significance was defined as
p < 0.05.
Results
Concordance of ALK IHC and FISH
Using the newly developed antibody, ALK (D5F3), we
analyzed ALK expression in 297 lung adenocarcinoma
cases. The cases with strongly or weakly positive ALKexpression showed readily appreciable cytoplasmic stain-
ing (Figures 1A and 1B). In contrast, the cases with
negative expression did not show any discernable stain-
ing (Figure 1C). Strong ALK expression was identified in
32 cases, weak expression in 12 cases and no expression
in 253 cases (Table 1).
FISH analysis was performed on the 297 cases to
evaluate ALK gene rearrangement status. Two hundred
and eighty-six out of 297 cases were informative for
FISH analysis and 33 cases were identified with ALK+
(Figure 1E). Thirty of the 33 ALK+ cases showed strong
ALK expression and the other 3 showed weak ALK ex-
pression. Therefore, there were 11 cases that showed
ALK expression but were ALK-. We re-reviewed the
FISH slides of the 11 discordant cases (2 cases with
strong and 9 cases with weak ALK expression), and 3
cases (1 with strong and 2 with weak ALK expression)
were identified as ALK+ while 8 (1 case with strong and
7 with weak ALK expression) were still ALK- (Table 1,
Figure 1F).
Regarding the 3 ALK+ cases, which were not identified
by the original FISH analysis, a case-by-case analysis re-
vealed the following:
Case 1 The dominant FISH signal pattern in this case
was more than one copy of a single green signal
without a corresponding orange signal in addition to
fused signals (Figure 1D). According to the ALK signal
enumeration guide, this indicated a deletion of the
orange portion of the ALK probe, which targeted the
drug targeting area. Therefore, we initially considered
this case as negative. After re-reviewing the FISH
analysis, we found there were some areas containing
scattered ALK+ cells with one or more copies of single
green signals in addition to fused signals and a single
red signal. The first 50 cells counted revealed 8 ALK+
cells. The second and third cell count in another 100
cells by different readers revealed 6 and 7 ALK+ cells,
respectively. If the first and third 50-cell count was
considered, the average percentage of positive cells
reached 15%. Therefore, this sample should be
considered positive.
Case 1 and 3 For these two cases, originally
constructed on TMA and IHC, analysis showed
strongly positive staining in one core and weakly
positive staining in the other. After re-reviewing the
FISH slides, we found that there was indeed a small
area of each core with a few cells containing subtle
break-apart signals. As cell counts were difficult to
perform in small areas containing not many cancer
cells, we cut the tissue sections. The IHC analysis still
demonstrated strongly and weakly positive ALK
expression, respectively. The FISH analysis in the
tissue sections showed ALK+.




FISH+ 31(96.9%) 5(41.7%) 0(0%) 36
FISH- 1(3.1%) 7(58.3%) 242(100%) 250
Total 32 12 242 286
astrongly positive ALK expression. b weakly positive ALK expression. cnegative
ALK expression.
Figure 1 Representative cases of IHC staining, FISH and qRT-PCR analysis in lung adenocarcinoma. (A-C) ALK IHC staining using CST’s
D5F3 antibody. (A) Cytoplasmic reactivity of strong intensity in tumor cells (original magnification, x40). (B) Weak to moderate cytoplasmic
reactivity in tumor cells (original magnification, x100). (C) No staining in tumor cells (original magnification, x200). (D-F) FISH analysis using Vysis
ALK Break-Apart probes. (D) The ALK+ case in which the majority of cells contained more than one copy of a single green signal without a
corresponding orange signal in addition to fused signals using FISH analysis. Green arrow represents more than one copy of a single green signal,
red arrow represents single red or split red-green signals indicative of ALK-rearrangement and yellow arrow represents touching red-green signals
not indicative of ALK-rearrangement. (E) ALK+ case with split red-green signals. (F) NSCLC case without ALK rearrangement. (G-I) VENTANA ALK
(D5F3) IHC assay revealed no expression in ALK- patients and strong expression in ALK+ patients. (G) Strong ALK expression (original magnifica-
tion, x20). (H) Unspecific staining (original magnification, x40). (I) No ALK expression (original magnification, x20). (G-L) Graphs from qRT–PCR
showing change in the normalized reporter signal (delta Rn) against PCR cycle number. (J) ALK fusion was detected at around 14 cycles of
qRT-PCR analysis in a case with strong ALK expression. (K) ALK fusion was detected at around 28 cycles in a case with weak ALK expression.
(L) No ALK fusion was detected with endogenous control gene, beta-actin, expressed normally.
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the 286 lung adenocarcinoma cases were identified
with ALK+. None of IHC negative cases were ALK+,
demonstrating 100% sensitivity. Eight IHC-positive cases
(1 strongly and 7 weakly positive cases) did not show ALK
gene rearrangement, resulting in 81.8% specificity. The
concordance rate of IHC and FISH is 97.2% (Table 1).
qRT-PCR and VENTANA ALK IHC analysis of discordant
cases
To further identify whether eight discordant cases of
IHC and FISH carried ALK fusion at the RNA level,
a qRT-PCR analysis was applied. Positive qRT-PCR
results were observed in 5 cases (1 strongly and 4
weakly positive cases) (Table 2). Among the 5 cases, 3
(1 strongly and 2 weakly positive cases) were shown to
have ALK expression using VENTANA ALK IHC ana-
lysis (Figure 1G). The ALK fusion in these 3 cases wasdetected at around 14 of 30 qRT-PCR cycles (Figure 1J).
Regarding the other two cases, although weak staining
in cancer cells could be observed (Figure 1H), they were
considered negative according to the manufacturer’s
scoring algorithm (details in Materials and Method sec-
tion). The ALK fusion in these 2 cases was detected at
around 28 of 30 qRT-PCR cycles (Figure 1K). The
remaining 3 of the 8 discordant cases showed neither
Table 2 VENTANA IHC and qRT-PCR analysis of all weakly










9 Positive 1+ Positive EML4-ALK variant 1/2/3a/3b
37 Positive 1+ Positive EML4-ALK variant 1/2/3a/3b
67 Positive 1+ Positive EML4-ALK variant 1/2/3a/3b
94 Positive 1+ Positive EML4-ALK variant 1/2/3a/3b
98 Positive 1+ Positive EML4-ALK variant 1/2/3a/3b
28 Negative 2+ Positive EML4-ALK variant 1/2/3a/3b
171 Negative 1+ Positive EML4-ALK variant 1/2/3a/3b
203 Negative 1+ Positive EML4-ALK variant 1/2/3a/3b
21 Negative 1+ Negative EML4-ALK variant 1/2/3a/3b
36 Negative 1+ Negative EML4-ALK variant 1/2/3a/3b
41 Negative 1+ Negative Negative
39 Negative 1+ Negative Negative
74 Negative 1+ Negative Negative
Table 3 Clinicopathologic comparisons between EML4–
ALK fusion-positive and fusion-negative lung
adenocarcinomas
Overall EML4–ALK(+) EML4–ALK(−)
n = 287 n = 37 (%) n = 250 (%) P value
Age Mean ± SD 48.16 ± 11.529 58.17 ± 10.03 <0.001
Median 48 58
Range 24-70 25-81
Sex Male 20(13.1) 133(86.9) 0.999
Female 17(13.1) 113(86.9)
Nonavailable 0 4
Smoking Never smoker 22(13.8) 138(86.2) 0.239




Mean ± SD 38.42 ± 24.263 37.59 ± 16.837 0.872
Median 32.50 35.00
Range 7-100 10-90








pTNM stages pStage I 2(2.5) 79(97.5) 0.028
pStage II 9(12.2) 65(87.8)
pStage III 9(14.3) 54(85.7)
Nonavailable 17 52
Shan et al. Diagnostic Pathology 2014, 9:3 Page 5 of 7
http://www.diagnosticpathology.org/content/9/1/3VENTANA ALK staining nor ALK fusion (Figures 1I
and 1L).
VENTANA ALK IHC and qRT-PCR assays were also
applied to the remaining 5 of the 12 ALK weakly
expressed cases, which were concordant with FISH ana-
lysis. These 5 cases were shown to have ALK expression
detected by VENTANA ALK IHC, and ALK fusion re-
vealed by qRT-PCR analysis (Table 2).
Clinicopathological characteristics of patients with ALK+
Using FISH analysis as a standard detection method, the
clinicopathological characteristics of the ALK+ and ALK-
patients were compared and the results are shown in
Table 3. As the median ages of the positive and negative
groups were 48 and 58 years, respectively, the ALK+ pa-
tients were significantly younger (p <0.001). Patients
with ALK+ were more likely to have lymph node metas-
tasis compared to ALK- patients (p = 0.002). No correl-
ation was observed between ALK+ and ALK- cases in
terms of sex, smoking habit, tumor size, pT, M factors
or pathologic TNM stage.
Discussion
In this study, we applied IHC and FISH analyses using
CST’s D5F3 antibody in a Chinese lung adenocarcinoma
sample cohort. An accurate FISH analysis depends
on multiple factors including fine equipment, skilled
personnel, well-preserved FFPE samples, enough cancer
cells, etc. In this study, two cores in TMAs were not
identified with ALK+ in initial FISH analysis due to a
lack of cancer cells. Similarly, in biopsies, the numbers
of cancer cells is often very limited, making an accurateFISH analysis difficult. With the IHC analysis in this
study, almost all of the cancer cells in the two cores
showed ALK expression, despite the fact that only a few
ALK+ cells were revealed by FISH analysis. A <100% rate
of cellular positivity in ALK+ tumors has been demon-
strated to be due to the technical limitations of FISH
analysis [13]. Therefore, combining IHC and FISH ana-
lyses results in ALK status being more accurately evalu-
ated in biopsies.
IHC analysis using CST’s D5F3 antibody has been
demonstrated with 100% sensitivity [12,14-16], suggest-
ing that IHC analysis is an effective way to prescreen pa-
tients for FISH analysis in the clinical diagnosis process
[14,15,17]. For IHC negative cases, FISH analysis is not
necessary. In strongly positive IHC cases, FISH analysis
also may not be necessary. Although there was one
strongly positive IHC case, which was shown with ALK-
by FISH analysis, the VENTANA ALK assay and qRT-
PCR analysis revealed ALK expression and ALK fusion,
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cancer patient with IHC-positive and FISH-negative ALK
had a dramatic response to crizotinib [18]. Therefore, the
patient in our case may benefit from crizotinib.
Weakly positive IHC cases must be carefully exam-
ined. In this study, 7 out of 12 (58.3%) weakly positive
cases were discordant with FISH analysis. Using the
VENTANA ALK IHC assay, three out of the seven
weakly positive cases showed ALK expression and could
be treated with crizotinib. Using qRT-PCR analysis, five
out of the seven weakly positive cases showed ALK
fusion at the RNA level. Therefore, there were two cases
in which the qRT-PCR analysis result was discordant
with the VENTANA ALK IHC assay. Compared to
negatively expressed ALK cases without any staining
(Figure 1I), these two cases were indeed weakly stained
in cancer cells using the VENTANA ALK IHC analysis
(Figure 1H). However, according to the VENTANA ALK
IHC assay scoring algorithm, the weak staining in these
two cases was regarded as unspecific and thus consid-
ered negative. Although qRT-PCR analysis demonstrated
ALK fusion in these two cases, it was detected in a very
late stage of the qRT-PCR process. We speculated that
the percentage of tumor cells with ALK fusion might
be very low in these two cases. However, with very
high sensitivity (1 in 100 DNA), they would still be
detected by qRT-PCR analysis. Whether these two
patients would benefit from crizotinib was difficult to
predict, as no relevant study has been reported. Further
study is required.
Previous reports have shown that ALK+ lung cancers
are characterized by younger patients, non-smokers
or light smokers when compared with ALK- patients
[6,7,19-23]. In this study, the ALK+ patients were signifi-
cantly younger and more likely to have lymph node me-
tastasis compared to ALK- patients. However, ALK+ and
ALK- lung adenocarcinomas showed no difference in
sex, smoking habit, tumor size, pT, M factors or patho-
logic TNM stage. The screening was limited in this study
to the lung adenocarcinomas of Chinese patients. There
may be an underlying difference in the subject popula-
tion by race and clinical characteristics.
In conclusion, with advantages such as a low cost and
100% sensitivity, IHC with CST’s D5F3 antibody can
serve as a robust diagnostic tool with which to routinely
screen lung adenocarcinoma patients with ALK+ in
pathology labs that do not have access to VENTANA
automated IHC platforms. For weakly expressed ALK
cases, qRT-PCR analysis, especially when applied on
FFPE samples, is suggested as a diagnostic test for ALK
fusion detection.Competing interest
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